Vanda Pharmaceuticals (NASDAQ:VNDA) Stock Rating Upgraded by Wall Street Zen

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued to clients and investors on Saturday.

Several other equities analysts have also commented on the stock. Cantor Fitzgerald reissued an "overweight" rating and issued a $13.00 target price on shares of Vanda Pharmaceuticals in a report on Wednesday, May 14th. HC Wainwright reissued a "buy" rating and issued a $20.00 target price on shares of Vanda Pharmaceuticals in a report on Wednesday, May 7th.

Vanda Pharmaceuticals Stock Performance

NASDAQ:VNDA traded down $0.12 during mid-day trading on Friday, reaching $4.51. 361,867 shares of the company's stock were exchanged, compared to its average volume of 640,730. Vanda Pharmaceuticals has a one year low of $3.81 and a one year high of $6.67. The firm has a market capitalization of $265.79 million, a PE ratio of -14.09 and a beta of 0.66. The business's fifty day simple moving average is $4.32 and its two-hundred day simple moving average is $4.55.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last released its earnings results on Wednesday, May 7th. The biopharmaceutical company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.05. Vanda Pharmaceuticals had a negative net margin of 9.51% and a negative return on equity of 3.49%. The firm had revenue of $50.04 million for the quarter, compared to analyst estimates of $45.13 million. As a group, equities research analysts forecast that Vanda Pharmaceuticals will post -1.12 EPS for the current year.

Insider Activity

In other Vanda Pharmaceuticals news, CEO Mihael Hristos Polymeropoulos bought 10,000 shares of the business's stock in a transaction that occurred on Wednesday, May 21st. The shares were acquired at an average cost of $4.40 per share, for a total transaction of $44,000.00. Following the transaction, the chief executive officer now directly owns 2,325,731 shares in the company, valued at approximately $10,233,216.40. This represents a 0.43% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 10.00% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Vanda Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the business. PVG Asset Management Corp acquired a new stake in Vanda Pharmaceuticals during the 1st quarter worth approximately $48,000. Millennium Management LLC boosted its position in Vanda Pharmaceuticals by 220.0% during the 1st quarter. Millennium Management LLC now owns 2,139,591 shares of the biopharmaceutical company's stock worth $9,821,000 after buying an additional 1,470,898 shares during the period. Royal Bank of Canada boosted its position in Vanda Pharmaceuticals by 34.3% during the 1st quarter. Royal Bank of Canada now owns 55,713 shares of the biopharmaceutical company's stock worth $256,000 after buying an additional 14,232 shares during the period. MetLife Investment Management LLC boosted its position in Vanda Pharmaceuticals by 18.9% during the 1st quarter. MetLife Investment Management LLC now owns 32,816 shares of the biopharmaceutical company's stock worth $151,000 after buying an additional 5,210 shares during the period. Finally, Stonepine Capital Management LLC boosted its position in Vanda Pharmaceuticals by 40.6% during the 1st quarter. Stonepine Capital Management LLC now owns 35,148 shares of the biopharmaceutical company's stock worth $161,000 after buying an additional 10,148 shares during the period. 88.14% of the stock is currently owned by institutional investors and hedge funds.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.